Introduction
The objective of this survey is to compile policies towards publication bias that are applied by European regulatory institutions in charge of benefit assessments of pharmaceuticals in the context of reimbursement and pricing decisions. Benefit assessments, also named clinical effectiveness assessments, postlicensing evaluations or health technology assessments (HTA), are increasingly used as an essential factor in determining reimbursement and pricing of pharmaceuticals in European countries and elsewhere. Generally speaking, funding agencies and policymakers seek to make healthcare decisions based on the entire relevant research evidence base. However, this can frequently not be achieved, to a large part because a considerable amount of research findings are or not published or are incomplete.
The following survey consists of two parts:
In Part A we kindly ask you to fill in a questionnaire addressing your institution's policy towards unpublished or incomplete data.
In Part B we kindly ask you to review and supplement drafted information to describe the process of benefit assessment and decisionmaking on reimbursement and pricing of pharmaceuticals in your country and to provide supplementary material addressing institutions' policy towards unpublished or incomplete data in your country.
Required time approx. 45-60 min.
We thank you very much for your participation! PART A: Institutional policy towards unpublished or incomplete data.
In Part A of the survey we kindly ask you to fill in a questionnaire addressing your institution's policy towards unpublished or incomplete data. In order to facilitate filling in the questionnaire, most answers are prephrased. At few points of the questionnaire, however, we kindly ask you to provide some written comments. Please click NEXT to start the questionnaire. 7. Which bibliographic databases are required to be searched in order to identify information on pharmaceutical benefit? (Please tick all options that apply)
What kind
 Medline  Embase  Cochrane Library  CINAHL  PsychINFO  TRIP-Database  CRD Databases (DARE, NHS-EED, HTA-Database)  Other (please specify)
Bibliographic database search is required to be supplemented by … (Please tick all options that apply)
 … hand search of reference lists  … hand search in selected relevant journals  … search for grey literature (e.g. academic papers, research reports, governmental reports, business and industry document, etc.)  ... search for part published studies (e.g. congress or conference abstracts, posters, proceedings)  There is no requirement to supplement bibliographic database search.  Other (please specify) IF information from clinical trial (meta) registries is used as source for benefit assessments of pharmaceuticals, please answer the following questions. IF NOT, please continue with the NEXT page.  Noncommercial sponsorship or funding of studies  Study registries as standard source of information for benefit assessments  Mandatory registration of clinical studies at inception  Mandatory standardised posting of full study protocols to study registries  Mandatory standardised posting of full study results to study registries  Quality standards for study registries  Public access to study registries  Public access to national regulatory databases  Public access to European Medicines Agency's databases  Public access to study reports prepared for regulatory drug approval  Public access to studies methods and results of older studies not covered by mandatory study registration  Data sharing procedures between regulatory authorities and benefit assessment/HTA bodies  Legal obligation for manufacturers to submit all requested evidence  Requirement for manufacturers to sign a statement or agreement declaring that all relevant evidence has been submitted  Financial sanctions for manufacturers not complying to submission requirements  Nonfinancial sanctions for manufacturers not complying to submission requirements  None  Other (please specify) 27. Please answer from the viewpoint of your institution: Which of the following policies should be ADDITIONALLY applied in your country in order to avoid bias due to unpublished or incomplete data in benefit assessment and decision-making on reimbursement and pricing of pharmaceuticals? (Please tick all options that apply)
Which clinical trial registries or meta-registries are required to be searched in order to identify information on pharmaceutical benefit? (Please tick all options that apply)
 Noncommercial sponsorship or funding of studies  Study registries as standard source of information for benefit assessments  Mandatory registration of clinical studies at inception  Mandatory standardised posting of full study protocols to study registries  Mandatory standardised posting of full study results to study registries  Quality standards for study registries  Public access to study registries  Public access to national regulatory databases  Public access to European Medicines Agency's databases  Public access to study reports prepared for regulatory drug approval  Public access to studies methods and results of older studies not covered by mandatory study registration  Data sharing procedures between regulatory authorities and benefit assessment/HTA bodies  Legal obligation for manufacturers to submit all requested evidence  Requirement for manufacturers to sign a statement or agreement declaring that all relevant evidence has been submitted  Financial sanctions for manufacturers not complying to submission requirements  Nonfinancial sanctions for manufacturers not complying to submission requirements  None  Other (please specify) In summary, we kindly ask you 1. to shortly review the table and chart for completeness and correctness and give short answers to a few questions provided in a red box, 2. to provide additional material addressing the institutions' policies towards unpublished or incomplete data in your country (e.g. guideline, directive, code of procedure, law, provision, decree, official statement, statute, declaration, regulation, recommendation, guidance, manual, submission requirements, submission templates, description of methods, etc.).
Please find information and questions concerning your country in the attachment of your invitation email. Please send your comments and supplementary material to dimitra.panteli@tuberlin.de
Thank you for your participation and support!
